• Markets
    • icon
  • Companies
PXS · ASX

Pharmaxis Ltd (ASX:PXS)

AU$0.03

 -5.0E-4 (-1.639%)
ASX:Live
28/11/2023 11:41:18 AM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PXS Overview

PXS Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PXS

Website

Pharmaxis Ltd

Telephone

61.2.9454.7200

Address

Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086

Description

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.

PXS Price Chart

Key Stats

Market Cap

AU$23.12M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.06

Trade Value (12mth)

AU$5,994.00

1 week

-1.61%

1 month

-7.58%

YTD

-48.31%

1 year

-51.59%

All time high

4.31221

Key Fundamentals

EPS 3 yr Growth

-51.000%

EBITDA Margin

-121.40%

Operating Cashflow

-$7m

Free Cash Flow Return

-64.30%

ROIC

-100.40%

Interest Coverage

-70.50

Quick Ratio

2.10

Other Data

Shares on Issue (Fully Dilluted)

720m

HALO Sector

Healthcare

Next Company Report Date

14-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PXS Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

31 October 23

Quarterly Activities Report

×

Quarterly Activities Report

31 October 23

Investor presentation - quarterly update

×

Investor presentation - quarterly update

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Quarterly Activities Report

×

Quarterly Activities Report

31 March 23

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

31 March 22

R&D Showcase Presentations Webinar 2

×

R&D Showcase Presentations Webinar 2

31 July 23

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

31 July 23

Quarterly Activities Report

×

Quarterly Activities Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities Report

×

Quarterly Activities Report

31 January 23

Investor Presentation

×

Investor Presentation

31 January 22

First Patients Dosed in PXS Scar Reduction Trial

×

First Patients Dosed in PXS Scar Reduction Trial

31 January 22

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities Report

×

Quarterly Activities Report

31 January 22

Presentation - quarterly investor update

×

Presentation - quarterly investor update

31 January 22

Updated Investor Presentation

×

Updated Investor Presentation

31 January 18

Investor Presentation - 30 January 2018

×

Investor Presentation - 30 January 2018

30 October 23

PXS Quarterly Shareholder Update and Investor Call

×

PXS Quarterly Shareholder Update and Investor Call

30 October 19

CEO Presentation to 2019 AusBiotech Conference

×

CEO Presentation to 2019 AusBiotech Conference

30 November 21

Application for quotation of securities - PXS

×

Application for quotation of securities - PXS

30 May 22

Notification of cessation of securities - PXS

×

Notification of cessation of securities - PXS

30 May 22

Application for quotation of securities - PXS

×

Application for quotation of securities - PXS

30 May 22

Application for quotation of securities - PXS

×

Application for quotation of securities - PXS

30 August 22

Preliminary Final Report

×

Preliminary Final Report

30 August 17

Pharmaxis Investor Presentation

×

Pharmaxis Investor Presentation

30 April 20

Pharmaxis CEO to Present at Virtual Health Conference

×

Pharmaxis CEO to Present at Virtual Health Conference

29 September 11

2011 Annual Report to Shareholders

×

2011 Annual Report to Shareholders

PXS Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.00 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.00 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 79.3 53.4 -408.8 Lock Lock Lock
     PE X Lock Lock Lock Lock 12.7 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 3.0 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.02 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.01 -0.03 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 93.3 -830.6 46.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock 7.6 -44.2 -23.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.02 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 208.5 365.7 -30.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 407 563 656 Lock Lock Lock
Basic m Lock Lock Lock Lock 407 563 656 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 23 10 13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 222.3 -56.9 32.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 7 -7 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 179.4 -191.4 55.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 31.8 -67.5 -22.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 68 168 123 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -1 -17 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 92.9 -1,234.7 5.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5.5 -170.7 -121.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 3 3 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -20 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 78.9 -352.4 11.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -19.4 -203.9 -135.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -7 -17 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -5 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -2 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 78.7 34.8 -486.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -13.1 -19.8 -87.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 3 -16 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 2 7 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 3 -16 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 120.2 -690.1 54.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.1 -1.7 -0.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 19 9 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 34 25 24 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 4 2 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -5 -7 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 31 14 14 Lock Lock Lock
Equity $m Lock Lock Lock Lock 3 11 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 7 13 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.0 83.1 -26.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -8.8 -7.7 -47.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -104.4 -17.9 -118.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.9 -164.1 -131.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -39.9 -19.2 -100.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 41.3 -159.4 -64.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -3.4 N/A -70.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 9.9 0.3 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -435.5 -43.0 -75.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.2 3.2 2.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.7 2.8 2.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 73.9 46.5 49.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 39.0 -264.0 -90.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.7 1.9 1.7 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.9 5.5 8.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.3 0.7 1.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 5.5 6.3 12.2 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -13.8 -70.0 -128.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -9.3 -27.1 -69.1 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -8.8 -7.7 -47.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 11.8 2.3 2.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -104.4 -17.9 -118.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -104.4 -17.9 -118.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 74.1 66.7 45.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 77.9 193.9 212.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 152.1 260.6 258.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 33.3 22.5 26.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 118.8 238.1 232.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PXS Shortsell

Frequently Asked Questions

The current share price of Pharmaxis Ltd (PXS:ASX) is AU$0.03.
The 52-week high share price for Pharmaxis Ltd (PXS:ASX) is AU$0.06.
The 52-week low share price for Pharmaxis Ltd (PXS:ASX)? is AU$0.03.
Pharmaxis Ltd (PXS:ASX) does not pay a dividend.
Pharmaxis Ltd (PXS:ASX) does not pay a dividend.
Pharmaxis Ltd (PXS:ASX) has a franking level of 0%.
Pharmaxis Ltd (PXS:ASX) is classified in the Healthcare.
The current P/E ratio for Pharmaxis Ltd (PXS:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.